Engineering Prodrug Nanomedicine for Cancer Immunotherapy
文献类型：期刊论文
| 作者 | Yang, Bin1,2; Gao, Jing1,2; Pei, Qing1; Xu, Huixiong2; Yu, Haijun1
|
| 刊名 | ADVANCED SCIENCE
 |
| 出版日期 | 2020-10-25 |
| 页码 | 33 |
| 关键词 | cancer immunotherapy combination immunotherapy nanomedicine prodrugs stimuli‐ responsive |
| DOI | 10.1002/advs.202002365 |
| 通讯作者 | Xu, Huixiong(xuhuixiong@126.com) ; Yu, Haijun(hjyu@simm.ac.cn) |
| 英文摘要 | Immunotherapy has shifted the clinical paradigm of cancer management. However, despite promising initial progress, immunotherapeutic approaches to cancer still suffer from relatively low response rates and the possibility of severe side effects, likely due to the low inherent immunogenicity of tumor cells, the immunosuppressive tumor microenvironment, and significant inter- and intratumoral heterogeneity. Recently, nanoformulations of prodrugs have been explored as a means to enhance cancer immunotherapy by simultaneously eliciting antitumor immune responses and reversing local immunosuppression. Prodrug nanomedicines, which integrate engineering advances in chemistry, oncoimmunology, and material science, are rationally designed through chemically modifying small molecule drugs, peptides, or antibodies to yield increased bioavailability and spatiotemporal control of drug release and activation at the target sites. Such strategies can help reduce adverse effects and enable codelivery of multiple immune modulators to yield synergistic cancer immunotherapy. In this review article, recent advances and translational challenges facing prodrug nanomedicines for cancer immunotherapy are overviewed. Last, key considerations are outlined for future efforts to advance prodrug nanomedicines aimed to improve antitumor immune responses and combat immune tolerogenic microenvironments. |
| WOS关键词 | IMMUNOGENIC CELL-DEATH ; REGULATORY T-CELLS ; TARGETED DELIVERY ; PROGRAMMED CELL-DEATH-1 ; CHECKPOINT BLOCKADE ; IN-VITRO ; NANOPARTICLES ; THERAPY ; PACLITAXEL ; INNATE |
| 资助项目 | National Natural Science Foundation of China[51873228] ; National Natural Science Foundation of China[31671024] ; National Natural Science Foundation of China[81671695] ; National Natural Science Foundation of China[81725008] ; National Natural Science Foundation of China[81927801] ; International Cooperation Project of Science and Technology Commission of Shanghai Municipality[20430711800] ; Shanghai Municipal Health Commission[2019LJ21] ; Shanghai Municipal Health Commission[SHSLCZDZK03502] ; Science and Technology Commission of Shanghai Municipality[19441903200] ; Youth Innovation Promotion Association of Chinese Academy of Sciences[2014218] ; Shanghai Institute of Materia Medica, CAS[FU-SIMM-20182006] ; Open Fund of the State Key Laboratory of Drug Research[SIMM2004KF-04] ; Fudan University[FU-SIMM-20182006] |
| WOS研究方向 | Chemistry ; Science & Technology - Other Topics ; Materials Science |
| 语种 | 英语 |
| WOS记录号 | WOS:000583188100001 |
| 出版者 | WILEY |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/291046]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Xu, Huixiong; Yu, Haijun |
| 作者单位 | 1.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 2.Tongji Univ, Shanghai Peoples Hosp 10, Ultrasound Res & Educ Inst, Dept Med Ultrasound,Sch Med,Canc Ctr, Shanghai 200072, Peoples R China |
| 推荐引用方式 GB/T 7714 | Yang, Bin,Gao, Jing,Pei, Qing,et al. Engineering Prodrug Nanomedicine for Cancer Immunotherapy[J]. ADVANCED SCIENCE,2020:33. |
| APA | Yang, Bin,Gao, Jing,Pei, Qing,Xu, Huixiong,&Yu, Haijun.(2020).Engineering Prodrug Nanomedicine for Cancer Immunotherapy.ADVANCED SCIENCE,33. |
| MLA | Yang, Bin,et al."Engineering Prodrug Nanomedicine for Cancer Immunotherapy".ADVANCED SCIENCE (2020):33. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。